Viromed Medical AG: insider trades · Germany · BaFin

About Viromed Medical AG

Viromed Medical AG is a German medical technology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. The group focuses on the development, manufacturing, and commercialization of cold atmospheric plasma (CAP) solutions, positioning itself in high-value clinical applications such as disinfection, wound healing, and selected intensive-care and pulmonology use cases. According to the company, it has been conducting basic research into viruses and bacteria since 2004 and highlighted pioneering disinfection work as early as the SARS period in 2013. The investment case is therefore built around an innovation-led medtech platform rather than a mature, broad-based device franchise. citeturn3view1turn3view3turn3view06 From a corporate structure standpoint, Viromed Medical AG is a listed holding company whose operating business is carried by its wholly owned subsidiary Viromed Medical GmbH. The company’s registered office is in Rellingen, Germany, while its stock-market communications also reference Pinneberg as a key operational location. Viromed emphasizes a broad commercial network in Germany and the wider DACH region, including hospitals, pharmacies, medical practices, elderly-care facilities, and institutional customers, alongside distribution partnerships abroad. This gives the group a relatively wide outreach for a small-cap medtech name, although commercial penetration remains tied to the adoption of its CAP platform. citeturn3view0turn3view3turn2search76 The product portfolio centers on CAP-based medical devices and applications, especially ViroCAP® and PulmoPlas®. These solutions are designed to address infection-related and wound-care use cases, with Viromed presenting CAP as a potentially disruptive approach to conventional treatment methods. In 2025, the company broadened its scope through the acquisition of pharmedix GmbH, which is active in health products, nutritional supplements, and medical cosmetics. That transaction adds a consumer-health and adjacent wellness layer to the story, while the core equity thesis still depends primarily on the medical-device and therapeutic plasma platform. citeturn3view2turn3view46 In competitive terms, Viromed remains a niche player in an emerging market. Its competitive positioning is driven less by scale than by clinical validation, regulatory progress, and the ability to convert preclinical and early clinical data into revenue. That makes execution risk material, but it also creates optionality if the technology gains broader hospital adoption. A major milestone came in 2025 with ISO 13485 certification, which is important for medical-device manufacturing and market access, and the company also advanced the approval pathway for PulmoPlas® with the relevant German authorities. citeturn3view26 Recent corporate and market developments have been meaningful. Viromed successfully started trading on Xetra in September 2024, improving liquidity and expanding its investor base. In 2025, it announced encouraging preclinical findings in respiratory indications, new distribution partnerships for Asia, veterinary medicine, and European cosmetics, and a stronger commercial outlook than in 2024. For international investors, Viromed is best viewed as a German small-cap medtech story with a high innovation quotient, meaningful regulatory milestones, and a growth narrative still dependent on clinical proof, commercialization, and execution. citeturn3view3turn3view2turn3view46